OncoMatch/Clinical Trials/NCT04803994
The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma
Is NCT04803994 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Atezolizumab and Bevacizumab for hepatocellular carcinoma.
Treatment: Atezolizumab · Bevacizumab — The ABC-HCC trial is a Phase IIIb, randomised, multicenter, open-label study designed to evaluate the safety and efficacy of atezolizumab plus bevacizumab versus TACE in patients with intermediate-stage HCC. Approximately 434 patients in two arms of treatment will be enrolled.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Disease stage
Required: Stage INTERMEDIATE
Intermediate stage HCC as defined by the following criteria: Disease not amenable to curative surgery, liver transplantation or curative ablation BUT disease amenable to TACE at enrollment as judged by the investigator.
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: PD-1/PD-L1/CTLA-4 inhibitor (atezolizumab, bevacizumab)
Previous treatment with atezolizumab or bevacizumab. Previous treatment with a programmed death 1 (PD1), programmed death-ligand (PD-L1), or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors, or any form of cancer immunotherapy for HCC.
Lab requirements
Blood counts
Platelet count, hemoglobin, neutrophil count (ANC), INR or aPTT must be normal or, if abnormal, not represent a contraindication for TACE and atezolizumab/bevacizumab as judged by the investigator.
Kidney function
Serum creatinine must be normal or, if abnormal, not represent a contraindication for TACE and atezolizumab/bevacizumab as judged by the investigator. Renal failure requiring hemo- or peritoneal dialysis [excluded].
Liver function
Total bilirubin ≤ 3.0 x ULN; ALT, AST, alkaline phosphatase, and serum albumin must be normal or, if abnormal, not represent a contraindication for TACE and atezolizumab/bevacizumab as judged by the investigator.
Adequate organ and bone marrow function. The following laboratory values obtained less than or equal to 7 days prior to randomization. Total bilirubin ≤ 3.0 x ULN...other laboratory values measured within 7 days prior to randomization are either normal or if abnormal do not represent a medical contraindication for TACE and atezolizumab/bevacizumab as judged by the investigator: Platelet count, hemoglobin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), serum creatinine, INR or aPTT, alkaline phosphatase, neutrophil count (ANC), and serum albumin.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify